Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 16/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 12/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 10/20 | 1.00 |
| ▸ | HDAC4 | P56524 | 10/20 | 1.00 |
| ▸ | HDAC7 | Q8WUI4 | 10/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 10/20 | 1.00 |
| ▸ | HDAC10 | Q969S8 | 10/20 | 1.00 |
| ▸ | HDAC8 | Q9BY41 | 10/20 | 1.00 |
| ▸ | HDAC9 | Q9UKV0 | 10/20 | 1.00 |
| ▸ | HDAC5 | Q9UQL6 | 10/20 | 1.00 |
| ▸ | HDAC11 | Q96DB2 | 9/20 | 1.00 |
| ▸ | CRHBP | P24387 | 1/20 | 0.41 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.41 |
| ▸ | TOP2A | P11388 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trichostatin SCHEMBL446807 | 1.00 | HDAC1 (1.00) | HDAC1HDAC6HDAC3HDAC4HDAC7 | |
| Trichostatin SCHEMBL19886 | 1.00 | HDAC1 (1.00) | HDAC1HDAC6HDAC3HDAC4HDAC7 | |
| Trichostatin SCHEMBL675951 | 1.00 | HDAC1 (1.00) | HDAC1HDAC6HDAC3HDAC4HDAC7 | |
| Trichostatin SCHEMBL16380793 | 1.00 | HDAC1 (1.00) | HDAC1HDAC6HDAC3HDAC4HDAC7 | |
| Trichostatin SCHEMBL29450582 | 0.99 | HDAC1 (0.97) | HDAC1HDAC6HDAC3HDAC4HDAC7 | |
| SCHEMBL21965902 | 0.91 | HDAC1 (0.83) | HDAC1HDAC6HDAC3HDAC4HDAC7 | |
| SCHEMBL10324242 | 0.90 | HDAC1 (0.81) | HDAC1HDAC6HDAC3HDAC4HDAC7 | |
| SCHEMBL17119540 | 0.88 | HDAC1 (0.79) | HDAC1HDAC6HDAC3HDAC4HDAC7 | |
| SCHEMBL14392626 | 0.87 | HDAC1 (0.77) | HDAC1HDAC6HDAC3HDAC4HDAC7 | |
| SCHEMBL13301372 | 0.87 | HDAC1 (0.77) | HDAC1HDAC6HDAC3HDAC4HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 317 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260007676-A1 | HDAC INHIBITORS FOR USE WITH NK CELL BASED THERAPIES | VIRACTA THERAPEUTICS INC (US) | 2026-01-08 | — | — | US | claimed |
| US-20240390375-A1 | METHODS AND COMPOSITIONS FOR TREATING VIRAL OR VIRALLY-INDUCED CONDITIONS | Viracta Subsidiary, Inc. (US) | 2024-11-28 | — | — | US | claimed |
| WO-2024192348-A2 | METHODS OF TREATING HPV IN HIV-INFECTED PATIENTS | OHIO STATE INNOVATION FOUNDATION (US) | 2024-09-19 | — | — | WO | claimed |
| US-20220249477-A1 | METHODS AND COMPOSITIONS FOR TREATING VIRAL OR VIRALLY-INDUCED CONDITIONS | VIRACTA THERAPEUTICS, INC. (US) | 2022-08-11 | — | — | US | claimed |
| US-20200368280-A1 | EPIGENETIC MODIFIERS FOR USE IN CELLULAR IMMUNOTHERAPY | Viracta Subsidiary, Inc. | 2020-11-26 | — | — | US | claimed |
| CN-110582564-A | derivation of liver organoids from human pluripotent stem cells | 新加坡科技研究局 | 2019-12-17 | — | — | CN | claimed |
| US-20190290646-A1 | HDAC INHIBITORS FOR USE WITH NK CELL BASED THERAPIES | INFINITY SA LLC, AS PURCHASER AGENT | 2019-09-26 | — | — | US | claimed |
| EP-3484489-A1 | HDAC INHIBITORS FOR USE WITH NK CELL BASED THERAPIES | Viracta Therapeutics, Inc. (US) | 2019-05-22 | — | — | EP | claimed |
| WO-2018013975-A1 | HDAC INHIBITORS FOR USE WITH NK CELL BASED THERAPIES | VIRACTA THERAPEUTICS, INC. (US) | 2018-01-18 | — | — | WO | claimed |
| US-20150056192-A1 | NOVEL COMPOSITIONS OF COMBINATIONS OF NON-COVALENT DNA BINDING AGENTS AND ANTI-CANCER AND/OR ANTI-INFLAMMATORY AGENTS AND THEIR USE IN DISEASE TREATMENT | INDUS PHARMACEUTICALS, INC. | 2015-02-26 | — | — | US | claimed |
| WO-2013151638-A1 | NOVEL COMPOSITIONS OF COMBINATIONS OF NON-COVALENT DNA BINDING AGENTS AND ANTI-CANCER AND/OR ANTI-INFLAMMATORY AGENTS AND THEIR USE IN DISEASE TREATMENT | INDUS PHARMACEUTICALS, INC. (US) | 2013-10-10 | — | — | WO | claimed |
| US-20120141524-A1 | ETHANOL EXTRACT OF ANTRODIA CAMPHORATA FOR INDUCING APOPTOSIS AND PREPARATION METHOD THEREOF | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2012-06-07 | — | — | US | claimed |
| US-20110245154-A1 | Methods and Compositions for Treating Viral or Virally-Induced Conditions | HEMAQUEST PHARMACEUTICALS, INC. (US) | 2011-10-06 | — | — | US | claimed |
| WO-2011113013-A2 | METHODS AND COMPOSITIONS FOR TREATING VIRAL OR VIRALLY-INDUCED CONDITIONS | HEMAQUEST PHARMACEUTICALS, INC. (US) | 2011-09-15 | — | — | WO | claimed |
| US-20100247543-A1 | TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES | ORYZON GENOMICS, S.A. (ES) | 2010-09-30 | — | — | US | claimed |
| US-20100210869-A1 | ETHANOL EXTRACT OF ANTRODIA CAMPHORATA FOR INDUCING APOPTOSIS AND PREPARATION METHOD THEREOF | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2010-08-19 | — | — | US | claimed |
| EP-2195029-A2 | TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES | Oryzon Genomics SA (ES) | 2010-06-16 | — | — | EP | claimed |
| WO-2009027349-A2 | TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES | ORYZON GENOMICS SA (ES) | 2009-03-05 | — | — | WO | claimed |
| WO-2008090534-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF EXCESSIVE WEIGHT GAIN, REDUCTION OF INAPPROPRIATE EATING BEHAVIOURS AND INHIBITION OF BINGE EATING FOR THE TREATMENT OF OBESITY | BERAND LIMITED (IE) | 2008-07-31 | — | — | WO | claimed |
| WO-2007049262-A1 | Methods and compositions for the promotion of neuronal growth and the treatment of asociality and affective disorders | BERAND LIMITED (IE) | 2007-05-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120141524-A1 | ETHANOL EXTRACT OF ANTRODIA CAMPHORATA FOR INDUCING APOPTOSIS AND PREPARATION METHOD THEREOF | BAX, API5, BCL2 | HDAC1 1322/4885HDAC6 2916/4885HDAC3 1120/4885 |
| US-20100210869-A1 | ETHANOL EXTRACT OF ANTRODIA CAMPHORATA FOR INDUCING APOPTOSIS AND PREPARATION METHOD THEREOF | BAX, API5, BCL2 | HDAC1 1322/4885HDAC6 2916/4885HDAC3 1120/4885 |
| US-20260007676-A1 | HDAC INHIBITORS FOR USE WITH NK CELL BASED THERAPIES | HDAC9, HDAC4, HDAC5 | HDAC1 11/4885HDAC6 10/4885HDAC3 5/4885 |
| US-20150056192-A1 | NOVEL COMPOSITIONS OF COMBINATIONS OF NON-COVALENT DNA BINDING AGENTS AND ANTI-CANCER AND/OR ANTI-INFLAMMATORY AGENTS AND THEIR USE IN DISEASE TREATMENT | TOP2A, HMGB1, TOP2B | HDAC1 311/4885HDAC6 405/4885HDAC3 502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.